関連する実験動画
Updated: Jul 14, 2026
05:41
Non-invasive Assessment of Microvascular and Endothelial Function
Published on: January 29, 2013
閉塞性心不全の患者におけるβ-アドレネルゲン受容体刺激に対する四肢血管の反応性
M A Creager1, R J Quigg, C J Ren
1Cardiovascular Division, Brigham and Women's Hospital, Boston, MA 02115.
Circulation
|June 1, 1991
まとめ
ベータアドレネルゲン受容体の無敏感化は,閉塞性心不全の患者において,四肢の血管拡張の障害を引き起こさない. イソプロテレノールとナトリウムニトロプロシドに対する四肢血流の反応は,心不全の患者で維持された.
科学分野:
- 心血管生理学 心血管の生理学
- 薬理学 薬理学とは
背景:
- 閉塞性心不全 (CHF) は,β-アドレナジックアゴニストに対する反応の低下と関連しています.
- CHFにおける肢体血管拡張障害における周辺ベータアドレノ受容体無感化の役割は不明である.
研究 の 目的:
- ベータ・アドレノ受容体への無感化が,慢性疾患の患者における異常な肢体血管拡張に寄与するかどうかを調査する.
主な方法:
- イソプロテレノール (ベータアゴニスト) とナトリウムニトロプルシド (血管拡張剤) の脳内動脈注入は,13人のCHF患者と14人の健康な対照群に投与されました.
- 前腕の血流は静脈閉塞プレシスモグラフィを用いて測定した.
- 反応性高血症の間,最大血管拡張の可能性が評価されました.
主要な成果:
- イソプロテレノールに対する最大前腕血流反応は,CHF患者と対照群で類似していました.
- イソプロテレノールとナトリウムニトロプロシドの投与量反応関係は,CHF患者で維持された.
- CHF患者の血ノルエピネフリン濃度の上昇は,イソプロテレノール反応と相関しませんでした.
結論:
- ベータ・アドレノ受容体の無敏感化は,閉塞性心不全の患者の肢体血管拡張障害の原因ではありません.
関連する概念動画
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:17Antihypertensive Drugs: Action of β1 Blockers
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:26Peripheral Artery Disease IV: Nursing Management
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses, temperature changes,...